Related Experiment Videos
Chromosome changes and splenectomy in Ph-positive CML. III. Predictive parameters in the chronic phase
Cancer Genetics and Cytogenetics
|January 15, 1985
Summary
Splenectomy in the blastic phase of Philadelphia chromosome-positive chronic myeloid leukemia (CML) improved survival for specific patients. Certain chromosomal abnormalities in the chronic phase may predict which patients benefit most from splenectomy.
Area of Science:
- Hematology
- Oncology
- Cytogenetics
Background:
- Philadelphia chromosome-positive chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- The blastic phase (BP) of CML is associated with a poor prognosis.
- Splenectomy is a potential intervention, but its role requires further clarification.
Purpose of the Study:
- To evaluate the impact of splenectomy on survival during the blastic phase of CML.
- To identify predictive parameters for splenectomy in the chronic phase (CP) of CML.
Main Methods:
- Retrospective analysis of cytogenetic data from CML patients.
- Comparison of survival outcomes between patients who underwent splenectomy and those who did not.
- Identification of chromosomal abnormalities in patients with specific marrow profiles.
Main Results:
- Splenectomy during the blastic phase prolonged survival in patients with Philadelphia chromosome-positive CML and only chromosomally abnormal cells in the marrow (AA patients).
- AA patients exhibited specific chromosomal abnormalities (trisomy 8, i(17q), -Y) during the chronic phase, years before the blastic phase.
- These chromosomal abnormalities were present only in the AA group.
Conclusions:
- Splenectomy during the blastic phase may improve survival for a subset of CML patients (AA patients).
- The presence of trisomy 8, i(17q), and/or a missing Y chromosome during the chronic phase could serve as a predictive marker for splenectomy benefit in CML.